Overview Schizophrenic Patients in Integrated Care Status: Terminated Trial end date: 2008-11-01 Target enrollment: Participant gender: Summary The purpose of the study is to investigate the well-being of schizophrenic patients treated with quetiapine XR combined with participation in the integrated care program compared to a treatment with quetiapine XR alone over a period of 18 month Phase: Phase 4 Details Lead Sponsor: AstraZenecaTreatments: Quetiapine Fumarate